Mark Erlander, PhD | Chief Scientific Officer
Dr. Erlander has a track record of over 20 years directing drug discovery efforts and developing precision cancer diagnostics. Dr. Erlander joined Trovagene in 2013 as Chief Scientific Officer (CSO). While at Trovagene, he has been instrumental in successfully transitioning the company from cancer-focused diagnostics to being at the forefront of precision cancer therapeutics. Dr. Erlander’s expertise in oncology precision therapeutics is focused on leveraging the intersection of targeted therapies with molecular diagnostics.
Prior to joining Trovagene, Dr. Erlander served as CSO at bioTheranostics, a bioMerieux company, which was previously AviaraDx and acquired by bioMerieux. As CSO, he led R&D, Medical & Scientific Affairs and clinical laboratory operations for the development of proprietary predictive tests in oncology for therapy decisions that are currently in treatment guidelines. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson. At J&J, Dr. Erlander led both efforts in drug discovery and the use of genomic technologies to identify new drug targets. Previous to this, he was an Assistant Professor at The Scripps Research Institute where he also received his post-doctoral training.
Dr. Erlander is an accomplished researcher in oncology therapeutics, diagnostics and genomic technologies with 44 issued U.S. patents and over 50 pending applications. He has co-authored over 90 scientific publications.
Dr. Erlander holds a BS degree in Biochemistry from the University of California, Davis; an MS degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles.